1. FDA’s decision to remove the breast cancer indication from the label of bevacizumab (Avastin).
2. Approval of Dendreon’s sipuleucel-T (Provenge), representing a new class of drug.
3. Sanofi-Aventis’ pursuit of Genzyme. It illustrates an industry move towards adding orphan and rare therapeutic areas to pharma portfolios. Another example of the trend came when Pfizer created orphan disease research division in 2010 and acquired FoldRx Pharmaceuticals.
To read the full, original article click on this link: Top Five Biotech Surprises & Innovations of 2010, and Five Trends to Watch for in 2011 | Xconomy
Author: N. Anthony Coles
